SCHEMBL16184191

SCHEMBL16184191

CNc1nc(-c2cnccn2)nc2c(OC)cc(-c3ccc(F)c(F)c3)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDGFRB P09619 2/20 0.39
▸ PDGFRA P16234 2/20 0.39
▸ CD38 P28907 1/20 0.37
▸ CYP17A1 P05093 1/20 0.35
▸ SCN9A Q15858 2/20 0.35
▸ TGFBR1 P36897 1/20 0.34
▸ TGFBR2 P37173 1/20 0.34
▸ CHRNA7 P36544 1/20 0.33
▸ MAP3K11 Q16584 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ LMNA P02545 2/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ CYP2D6 P10635 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ CYP2C19 P33261 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474183 0.91 KIT (0.39) PDGFRBPDGFRACD38SCN9ACHRNA7
SCHEMBL16184371 0.91 CYP17A1 (0.36) PDGFRBPDGFRACYP17A1CHRNA7KDM4E
SCHEMBL16184202 0.88 NPC1 (0.41) CD38CHRNA7KDM4EALDH1A1LMNA
SCHEMBL14474187 0.88 SCN9A (0.38) CD38SCN9ATGFBR1TGFBR2MAP3K11
SCHEMBL16184183 0.87 KIT (0.41) PDGFRBPDGFRASCN9ATGFBR1RAF1
SCHEMBL16184213 0.87 KIT (0.38) PDGFRBPDGFRACD38KDM4EALDH1A1
SCHEMBL16184204 0.87 SYK (0.43) PDGFRBPDGFRAALDH1A1LMNACYP1A2
SCHEMBL16184198 0.87 TGFBR1 (0.38) CD38SCN9ATGFBR1TGFBR2MAP3K11
SCHEMBL16184217 0.86 PDGFRB (0.39) PDGFRBPDGFRACD38KDM4EALDH1A1
SCHEMBL16184225 0.86 LIMK1 (0.35) CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB PDGFRB 2489/4885PDGFRA 2609/4885CD38 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback